J. Christopher Naftzger - 01 Feb 2024 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)

Role: General Counsel and CCO
Signature: /s/ David C. Hastings as attorney-in-fact for J. Christopher Naftzger
Issuer symbol: ABUS
Transactions as of: 01 Feb 2024
Net transactions value: $0
Form type: 4
Filing time: 05 Feb 2024, 19:55:14 UTC
Previous filing: 12 Jul 2023
Next filing: 05 Feb 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABUS	Common Shares	Award	$0	+95,100		$0.000000	95,100	01 Feb 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABUS	Stock Option (Right to Buy)	Award	$0	+380,500		$0.000000	380,500	01 Feb 2024	Common Shares	380,500	$2.40	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction.
F2	Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.
F3	This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date.